Table 2.
Comparison of clinical characteristics of patients with COVID-2019 at admission and discharge.
| Variables | Group A (n=20) | Group B (n=20) | Group C (n=20) | Total (n=60) | p-value |
|---|---|---|---|---|---|
| Blood routine | |||||
| Leucocytes (× 10⁹ /l) -abnormal (n, %) | 3 (15.0%) | 6 (30.0%) | 4 (20.0%) | 13 (21.7%) | 0.63* |
| Recovery (n, %) | 3 (100.0%) | 3 (50.0%) | 3 (75.0%) | 9 (69.2%) | |
| Neutrophils (× 10⁹ /l) -abnormal (n, %) | 6 (30.0%) | 4 (20.0) | 3 (15.0%) | 13 (21.7%) | 0.63* |
| Recovery (n, %) | 3 (50.0%) | 2 (50.0%) | 2 (66.7%) | 7 (53.8%) | |
| Lymphocytes (× 10⁹ /l) -abnormal (n, %) | 13 (65.0%) | 12 (60.0%) | 6 (30.0%) | 31 (51.7%) | 0.057 |
| Recovery (n, %) | 7 (53.8%) | 5 (41.7%) | 5 (83.3%) | 17 (54.8%) | |
| Platelets (× 10⁹/ l) -abnormal (n, %) | 4 (20.0%) | 3 (15.0%) | 1 (5.0%) | 8 (13.3%) | 0.51* |
| Recovery (n, %) | 1 (25.0%) | 2 (66.7%) | 1 (100.0%) | 4 (50.0%) | |
| Haemoglobin (g/l) -abnormal (n, %) | 1 (5.0%) | 6 (30.0%) | 5 (25.0%) | 12 (20.0%) | 0.19* |
| Recovery (n, %) | 1 (100.0%) | 2 (33.3%%) | 2 (40.0%) | 5 (41.7%) | |
| Coagulation function | |||||
| Prothrombin time (s) -abnormal (n, %) | 4 (20.0%) | 3 (15.0%) | 4 (20.0%) | 11 (18.3%) | 1.0* |
| Recovery (n, %) | 1 (25.0%) | 0 (0.0%) | 1 (25.0%) | 2 (18.2%) | |
| Activated partial thromboplastin time (s) -abnormal (n, %) | 4 (20.0%) | 2 (10.0%) | 3 (15.0%) | 9 (15.0%) | 0.90* |
| Recovery (n, %) | 2 (50.0%) | 2 (100.0%) | 3 (100.0%) | 7 (77.8%) | |
| D-dimer (µg/l) -abnormal (n, %) | 8 (40.0%) | 5 (25.0%) | 8 (40.0%) | 21 (26.3%) | 0.52 |
| Recovery (n, %) | - | - | - | - | - |
| Blood biochemistry | |||||
| Albumin (g/l) -abnormal (n, %) | 19 (95.0%) | 17 (85.0%) | 17 (85.0%) | 53 (88.3%) | 0.68* |
| Recovery (n, %) | 3 (15.8%) | 3 (17.6%) | 3 (17.6%) | 9 (17.0%) | |
| Alanine aminotransferase (U/l) -abnormal (n, %) | 11 (55.0%) | 6 (30.0%) | 11 (55.0%) | 28 (46.7%) | 0.19 |
| Recovery (n, %) | 6 (54.5%) | 3 (50.0%) | 3 (27.3%) | 12 (42.9%) | |
| Glutamic-oxalacetic transaminase (U/l) -abnormal (n, %) | 9 (45.0%) | 4 (20.0%) | 10 (50.0%) | 23 (38.3%) | 0.11 |
| Recovery (n, %) | 5 (55.6%) | 2 (50.0%) | 2 (20.0%) | 9 (39.1%) | |
| Total bilirubin (μmol/l) -abnormal (n, %) | 3 (15.0%) | 1 (5.0%) | 2 (10.0%) | 6 (10.0%) | 0.86* |
| Recovery (n, %) | 2 (66.7%) | 0 (0.0%) | 0 (0.0%) | 2 (33.3%) | |
| Carbamide (mmol/l) -abnormal (n, %) | 2 (10.0%) | 2 (10.0%) | 1 (5.0%) | 5 (8.3%) | 1.0* |
| Recovery (n, %) | 2 (100.0%) | 1 (50.0%) | 1 (100.0%) | 4 (75.0%) | |
| Serum creatinin (μmol/l) -abnormal (n, %) | 7 (35.0%) | 5 (25.0%) | 8 (40.0%) | 20 (33.3%) | 0.59 |
| Recovery (n, %) | 0 (0.0%) | 1 (20.0%) | 2 (25.0%) | 3 (15.0%) | |
| Creatine kinase (U/l) -abnormal (n, %) | 9 (45.0%) | 7 (35.0%) | 6 (30.0%) | 22 (36.7%) | 0.61 |
| Recovery (n, %) | 7 (77.8%) | 4 (57.1%) | 3 (50.0%) | 14 (63.6%) | |
| Creatine phosphokinase isoenzyme (U/l) -abnormal (n, %) | 4 (20.0%) | 0 (0.0%) | 0 (0.0%) | 4 (6.7%) | 0.030* |
| Recovery (n, %) | - | - | - | - | - |
| Lactate dehydrogenase (U/l) -abnormal (n, %) | 15 (75.0%) | 7 (35.0%) | 7 (35.0%) | 29 (48.3%) | 0.014 |
| Recovery (n, %) | 9 (60.0%) | 5 (71.4%) | 5 (71.4%) | 19 (65.5%) | |
| Infection-related biomarkers | |||||
| Interleukin-6 (pg/ml) -abnormal (n, %) | 13 (65.0%) | 13 (65.0%) | 10 (50.0%) | 36 (60.0%) | 0.54 |
| Recovery (n, %) | 1 (7.7%) | 1 (7.7%) | 4 (40.0%) | 6 (16.7%) | |
| C-reactive protein (mg/l) -abnormal (n, %) | 16 (80.0%) | 15 (75.0%) | 13 (65.0%) | 44 (73.3%) | 0.55 |
| Recovery (n, %) | 6 (37.5%) | 5 (33.3%) | 6 (46.2%) | 17 (38.6%) |